Synlett 2007(10): 1553-1556  
DOI: 10.1055/s-2007-982558
LETTER
© Georg Thieme Verlag Stuttgart · New York

An Efficient Synthesis of Enantiomerically Pure (1R,2S,5S)- and (1S,2R,5R)-Rosaprostol Methyl Esters

M. Carmen Murcia, Gabriela de la Herran, Joaquín Plumet, Aurelio G. Csaky*
Departamento de Química Orgánica, Facultad de Química, Universidad Complutense, 28040 Madrid, Spain
e-Mail: csaky@quim.ucm.es;
Further Information

Publication History

Received 29 March 2007
Publication Date:
06 June 2007 (online)

Abstract

We report a concise synthesis of the enantiomerically pure 1,2-trans-1,5-cis-methyl esters of rosaprostol, a prostaglandin derivative used for the treatment of gastric and duodenal ulcers, ­using as key step the chemo- and stereoselective Michael addition of a Grignard reagent to an unprotected hydroxycyclopentenone.

    References and Notes

  • 1a Valcavi U. Caponi R. Brambilla A. Palmira M. Minoja F. Bernini F. Musanti R. Fumagalli R. Arzneim.-Forsch.  1982,  32:  657 
  • 1b Adami M. Scarpignato C. Signorini G. Coruzzi G. Bertaccini G. Farmaco Ed. Prat.  1984,  39:  409 
  • 1c Fumagalli R. Caponi R. Corsini A. Brambilla A. Palmira M. Bernini F. Valcavi U. Prostaglandins  1985,  29:  467 
  • 1d Tincani GP. Maniscalco G. Gunelli M. Ciarrocchi V. Minerva Medica  1987,  78:  847 
  • 1e Aly A. Scand. J. Gastroenterol.  1987,  Suppl. 137:  43 
  • 1f Canonica GW. Ciprandi G. Scordamaglia A. Ruffoni S. Pizzorno G. Caria M. Cheli R. Ann. Allerg.  1988,  60:  541 
  • 1g Di Murro R. Camarri E. Ciani D. Mariotti L. Nencioni C. Romagnoli AM. Int. J. Clin. Pharm. Res.  1988,  8:  345 
  • 1h Foschi D. Trabucchi E. Galeone M. Ferrante F. Toti GL. Castoldi L. Musazzi M. Centenero A. Montorsi W. Int. J. Tissue React.  1988,  10:  53 
  • 1i Ciprandi G. Ruffoni S. Ciani D. Tosca MA. Canonica GW. Int. J. Immunol.  1989,  5:  81 
  • 1j Calcamuggi G. Babini G. Arduino C. Lanzio M. Anfossi G. Ciani D. Emanuelli G. Adv. Prostaglandin Thromboxane Leukotriene Res.  1991,  21B:  789 
  • 2a Valcavi U. inventors; DE  2535343. 
  • 2b Valcavi U, Innocenti S, Bosone E, Farina P, Marotta V, and Zabban GB. inventors; EP  155392. 
  • 2c Shono T. Kise N. Tetrahedron Lett.  1990,  31:  1303 
  • 2d Shono T. Kise N. Fujimoto T. Tominaga N. Morita H. J. Org. Chem.  1992,  57:  7175 
  • 2e Tanimori S. Kainuki T. Nakayama M. Biosci., Biotechnol., Biochem.  1992,  56:  1807 
  • 2f Mikolajczyk M. Zurawinski R. J. Org. Chem.  1998,  63:  8894 
  • 2g Mikolajczyk M. Mikina M. Zurawinski R. Pure Appl. Chem.  1999,  71:  473 
  • 2h Trost BM. Pinkerton AB. Org. Lett.  2000,  2:  1601 
  • 2i Mikolajczyk M. Mikina M. Jankowiak A. Mphahlele MJ. Synthesis  2000,  1075 
  • 2j Trost BM. Pinkerton AB. J. Org. Chem.  2001,  66:  7714 
  • 2k Mikolajczyk M. Phosphorus, Sulfur Silicon Relat. Elem.  2002,  177:  1839 
  • 2l Ghosh AK. Bilcer G. Schiltz G. Synthesis  2001,  2203 
  • 2m List B. Castello C. Synlett  2001,  1687 
  • 3 See for example: Breuer M. Ditrich K. Habicher T. Hauer B. Kesseler M. Stürmer R. Zelinski T. Angew. Chem. Int. Ed.  2004,  43:  788 ; and references cited therein
  • See for example:
  • 4a West FG. Gunawardena GU. J. Org. Chem.  1993,  58:  2402 
  • 4b West FG. Gunawardena GU. J. Org. Chem.  1993,  58:  5043 
  • 4c Johnson CR. Golebiowski A. Braun MP. Sundram H. Tetrahedron Lett.  1994,  35:  1833 
  • 4d Pudukulathan Z. Manna S. Hwang S.-W. Khnapure SP. Lawson JA. FitzGerald GA. Rokach J. J. Am. Chem. Soc.  1998,  120:  11953 
  • 4e Usami Y. Numata A. Synthesis  1999,  723 
  • 4f Harmata M. Lee DR. J. Am. Chem. Soc.  2002,  124:  14328 
  • 4g Rodriguez AR. Spur BW. Tetrahedron Lett.  2002,  43:  4575 
  • 5a Harre M. Raddatz P. Walenta R. Winterfeld E. Angew. Chem., Int. Ed. Engl.  1982,  21:  480 
  • 5b Collins PW. Djuric SW. Chem. Rev.  1993,  93:  1533 
  • 6a Csaky AG. Mba M. Plumet J. J. Org. Chem.  2001,  66:  9026 
  • 6b Csaky AG. Contreras C. Mba M. Plumet J. Synlett  2002,  1451 
  • 6c Csaky AG. Mba M. Plumet J. Synlett  2003,  2092 
  • 7 Rodríguez A. Nomen M. Spur BW. Godfroid JJ. Eur. J. Org. Chem.  1999,  2655 
  • 9 Babiak KA. Ng JS. Dygos JH. Weyker CL. J. Org. Chem.  1990,  55:  3377 
  • 11 For a recent preparation of (+)-2 from methyl oleate and 2,3-O-isopropylidene-d-glyceraldehyde, see: Muhammad Nor O. Hamilton RJ. J. Palm Oil Res.  2004,  16:  37 
  • 14 Csaky AG. Mba M. Plumet J. Tetrahedron: Asymmetry  2004,  15:  647 
  • 19 For a previous use of L-Selectride with KH2PO4 as proton source to convert an enone into an alcohol, see: Bell RA. Turner JV. Tetrahedron Lett.  1981,  22:  4871 
8

According to ref. 7, condensation of furan with suberic acid monomethyl ester afforded the corresponding furylketone, which was reduced to methyl-8-(2-furyl)-8-hydroxy-octanoate. This was transformed into methyl 7-(2-hydroxy-5-oxocyclopent-3-enyl)heptanoate by a Nazarov cyclization. Isomerization to rac-2 was best performed upon treatment with an aqueous phosphate buffer solution: To a solution of methyl 7-(2-hydroxy-5-oxocyclopent-3-enyl)heptanoate (1.28 g, 5.33 mmoL) in 1,4-dioxane (50 mL) was added a phosphate buffer solution (pH 8, 37 mL) and the mixture was heated at reflux for 30 h. Concentration under reduced pressure followed by extraction with EtOAc afforded an oil which was purified by chromatography (hexane-EOtAc, 8:2) to give rac-2 in 80% yield.

10

Enzymatic resolution of 2 was carried out according to ref. 9. For a more recent report of the resolution of 2, see ref. 7. Compounds (+)-2 and (-)-2 are commercially available (Aldrich).

12

(-)-Methyl 7-[(1 R ,2 R ,3 S )-2-Hexyl-3-hydroxy-5-oxocyclopentyl]heptanoate [(-)-3]
[α]D 25 -22 (c 3.5, CHCl3). R f = 0.22 (CH2Cl2-EtOAc, 8:2). 1H NMR (300 MHz, CDCl3): δ = 4.48 (m, 1 H), 3.67 (s, 3 H), 2.36-2.28 (m, 4 H), 2.13-2.05 (m, 1 H), 1.90-1.80 (m, 1 H), 1.66-1.50 (m, 8 H), 1.38-1.25 (m, 12 H), 0.93 (t, J = 6.6 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 219.8 (s), 175.0 (s), 75.2 (d), 51.8 (q), 50.6 (d), 48.6 (d), 47.0 (t), 39.7 (t), 32.5 (t), 30.5 (t), 30.0 (t), 28.6 (t), 28.3 (t), 27.6 (t), 27.02 (t), 26.8 (t), 23.8 (t), 23.1 (t), 14.5 (q) ppm.

13

(+)-Methyl 7-[(1 R ,2 S )-2-Hexyl-5-oxocyclopent-3-enyl)heptanoate [(+)-4]
[α]D 25 +34 (c 2.7, CHCl3). R f = 0.89 (CH2Cl2-EtOAc, 8:2). 1H NMR (300 MHz, CDCl3): δ = 7.60 (dd, 3 J = 1.59 Hz, 3 J = 5.67 Hz, 1 H), 6.1 (dd, 3 J = 1.68 Hz, 3 J = 5.70 Hz, 1 H), 3.67 (s, 3 H), 2.62-2.53 (m, 1 H), 2.30 (t, J = 7.35 Hz, 2 H), 1.98-1.89 (m, 1 H), 1.65-1.56 (m, 2 H), 1.37-1.23 (m, 18 H), 0.91-0.86 (m, 3 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 212.9 (s), 174.6 (s), 167.7 (d), 133.2 (d), 52.2 (d), 51.8 (q), 48.6 (d), 35.0 (t), 34.4 (t), 32.2 (t), 32.1 (t), 31.6 (t), 29.8 (t), 29.3 (t), 27.2 (t), 25.3 (t), 23.1 (t), 22.9 (t), 14.5 (q) ppm.

15

To a suspension of LiCl (0.52 mmol) in THF (0.75 mL) at 0 °C was added hexylmagnesium bromide (2 M solution in Et2O, 0.26 mL) and the mixture was stirred for 5 min. A solution of (-)-2 (0.23 mmol) in THF (0.75 mL) was added dropwise. The mixture was stirred at 0-10 °C for 18 h, and hydrolyzed with sat. NH4Cl. The organic layer was decanted and the aqueous layer extracted with Et2O. The combined organic layers were dried on MgSO4. Filtration and elimination of the solvent under reduced pressure afforded an oil that was purified by chromatography (CH2Cl2-EtOAc, 8:2).

16

To a solution of (-)-3 (0.14 mmol) in Et2O (2.2 mL) was added PTSA (0.035 mmol) and the solution was stirred at 25 °C for 18 h. The mixture was diluted with Et2O and washed with sat. NaHCO3 and brine. The organic layer was dried over MgSO4 and the solvent was eliminated under reduced pressure. The resulting oil was purified by chromatography (CH2Cl2-EtOAc, 8:2).

17

To a solution of (-)-2 (0.23 mmol) in THF (0.75 mL) at 0 °C was added dropwise a 2 M solution of hexylmagnesium bromide in Et2O (0.26 mL). The mixture was stirred from 0 °C to 30 °C for 36 h, and hydrolyzed with sat. NH4Cl solution. The organic layer was decanted and the aqueous layer extracted with Et2O. The combined organic layers were dried over MgSO4. Filtration and elimination of the solvent under reduced pressure afforded an oil that was purified by chromatography (CH2Cl2-EtOAc, 8:2).

18

To a solution of L-Selectride (0.3 mL) in THF (0.3 mL) at -78 °C was added dropwise a solution of 3 (0.1 mmol) in t-BuOH (20 µL) and THF (0.5 mL) and the mixture was stirred at -78 °C for 1 h. The mixture was hydrolyzed with sat. NH4Cl solution at -78 °C. The organic layer was decanted and the aqueous layer extracted with Et2O. The combined organic layers were dried over MgSO4. Filtration and elimination of the solvent under reduced pressure afforded an oil that was purified by chromatography (hexane-EtOAc, 8:2).

20

(+)-Methyl 7-[(1 R ,2 S ,5 S )-2-Hexyl-5-hydroxycyclopentyl]heptanoate [(+)-1]
[α]D 25 +13 (c 0.6, CHCl3). R f = 0.43 (hexane-EtOAc, 8:2). 1H NMR (300 MHz, CDCl3): δ = 4.25-4.18 (m,1 H), 3.68 (s, 3 H), 2.31 (t, J = 7.35 Hz, 2 H), 2.07-1.91 (m, 1 H), 1.91-1.77 (m, 1 H), 1.67-1.54 (m, 4 H), 1.37-1.22 (m, 20 H), 0.91-0.87 (m, 3 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 174.8 (s), 74.8 (d), 51.9 (q), 42.3 (d), 39.6 (d), 35.5 (t), 34.5 (t), 33.9 (t), 32.3 (t), 32.3 (t), 30.1 (t), 29.5 (t), 29.4 (t), 28.7 (t), 28.6 (t), 28.0 (t), 25.3 (t), 23.1 (t), 14.5 (q) ppm.

21

The cis relative stereochemistry of the OH and R1 groups in (+)-1 was unambiguously determined by COSY and NOE measurements. Saturation of the H5 signal (δ = 4.25-4.18 ppm, m, 1 H) afforded a 4% increase of the H2 signal (δ = 1.91-1.77 ppm, m, 1 H).